youkenafil

Youkenafil is a novel, selective phosphodiesterase type 5 (PDE5) inhibitor developed for the treatment of erectile dysfunction. It acts by inhibiting PDE5, an enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum, thereby enhancing nitric oxide–mediated vasodilation and facilitating erection. Youkenafil is primarily metabolized via cytochrome P450 enzymes CYP3A4/5. Clinical studies have shown that it is rapidly absorbed after oral administration and generally well tolerated at single doses up to 200 mg and multiple doses up to 150 mg daily. Food intake can reduce absorption efficiency but does not significantly affect overall exposure. Drug-drug interaction studies indicate that strong CYP3A4/5 inhibitors or inducers can markedly alter its pharmacokinetics[1][2][3][6][8].

Brand names

youkenafil hydrochlorideyonkenafil hydrochloride

Other names

youkenafil hydrochlorideyonkenafil hydrochloride